Merck has informed that recently Merck has implemented certain organisation changes which impact the roles and responsibilities of two whole time directors, viz. Brijesh Kapil and Ali Sleiman. As such Brijesh Kapil and Ali Sleiman, whole time directors, have expressed their inability to continue as directors on the Board of the Company and have tendered their resignation from the office of director of the Company effective from October 04, 2016. Additionally, the Company’s ultimate holding company, Merck KGaA, Germany, has changed the nomination non-executive director, Bradley Simpson, on the board of the Company and in his place has appointed Zoe Tang, Regional CFO Central Asia as member of the Board. The management places on record its appreciation for the valuable contributions made by Kapil, Sleiman and Simpson during their tenure as members of the Board of the Company.
The above information is a part of company’s filings submitted to BSE.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |